FT Health: Future of Antibiotics

Special ReportFT Health: Future of Antibiotics

This report examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them even for viral infections, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain

  • Antibiotic resistance kills over 1m people a year, says study

    Research underscores the dangers of bacteria developing the ability to resist drugs

  • Antibiotic accountability: how countries and companies perform

    FT dashboard tracks responses to the growing threat of antimicrobial resistance

  • Limited access to antibiotics is driving resistance, warns watchdog

    Failure to ensure they reach world’s poorest increases health risks, says pharma body

  • Pressure grows for funding to tackle ‘silent pandemic’ of antimicrobial resistance

    Political will is needed to address absence of sufficient financial incentives for new drugs

  • Push and pull: funding drugs to be used only sparingly

    New models are emerging to allow pharma companies to turn a profit regardless of how much new antibiotics are used

  • Video: Do we need a Netflix for antibiotics?

    FT’s Andrew Jack analyses new subscription models to pay for breakthrough medicines

More from this Special Report
  • The silent pandemic of antibiotic resistance

    A South African doctor’s prescription to stop poorer countries losing access to many of modern medicine’s advances

  • Antibiotic resistance: how to tackle a public health crisis

    Recommendations from two FT roundtables with pharma, government, and NGO experts

  • Overuse of antibiotics for meat production drives resistance in humans

    Household names like McDonald’s start to modify practices to aid farm animals’ health, growth and digestion

  • Covid delays India’s attempts to curb widespread overuse of antibiotics

    Some hospital schemes encourage proper antimicrobial stewardship but progress has been slow

  • The threat of antibiotic resistance — in charts

    Detailed information is starting to emerge on the problem and how to combat it

  • Non-profits fill gaps in the broken market for antibiotics

    Promising treatments in pipeline despite lack of financial incentives for pharma industry

  • Countries brace for ‘silent tsunami’ of antibiotic-resistant infections

    Over half a century after antibiotics revolutionised medicine, overuse threatens existing treatments while the pipeline of replacements is thin

  • Investors step up pressure on companies over use of antibiotics

    Amundi and Aviva among backers of initiative targeting food, retail and pharmaceutical groups

  • Video: How can we stop the next global health crisis?

    In the future even cuts can have fatal consequences, with drug resistant infections killing 10m people a year. Is this just a projection?

  • Antimicrobial resistance is the next battle

    Covid-19 is a warning that we must develop drugs to treat future threats


Owl Media Group takes pride in providing social-first platforms which equally benefit and facilitate engagement between businesses and consumers and creating much-needed balance to make conducting business, easier, safer, faster and better. The vision behind every platform in the Owl Media suite is to make lives better and foster a healthy environment in which parties can conduct business efficiently. Facilitating free and fair business relationships is crucial for any thriving economy and Owl Media bridges the gap and open doors for transparent and successful transacting. No advertising funds influence the functionality of our media platforms because we value authenticity and never compromise on quality no matter how lucrative the offers from advertisers may seem.

Originally posted on: https://www.ft.com/reports/future-antibiotics